Amicus Therapeutics (FOLD) Tops Q3 EPS by 3c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates
November 4, 2025 7:01 AM ESTQ3 2025 Total Revenue of $169M, up 17% at CER
Positive Q3 2025 GAAP Net Income of $17M
Cash Position of $264M, a $33M Increase in Q3 2025
Conference Call and Webcast Today at 8:30 a.m. ET
PRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:... More
